Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheum with a View

Richard S. Panush, MD  |  Issue: July 2011  |  July 12, 2011

Eric Matteson, MD, and I addressed these issues in a previous article, reviewing the available information regarding Wegener and suggesting that the time had come to stop using eponyms.3 Previously, Daniel Wallace, MD, and I, assisted by Rabbi Elliot Dorff, PhD, a leading ethicist, had persuaded international rheumatology editors to abandon “Reiter’s syndrome.” Reiter was president of the Reich Health Office and responsible for all experiments in concentration camps for reactive arthritis. When Ephraim Engleman, MD, who “named” Reiter’s syndrome in 1942, became aware of this, he agreed to retract his suggestion to use the term.4

I was disappointed that the board of directors of the ACR then declined to consider the issue of writer eponyms in 2007, when the Reiter retraction was published, but I am pleased that our organization and others are now confronting these challenging ethical issues. Kudos to them for their stand. They got this right.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Big Girls Don’t Cry”

This was one of my favorite songs growing up. Another was “Sherry” because I had an unrequited crush on a girl named Shari. I got a kick out of seeing Frankie Valli and the Four Seasons, who recorded these hits, live last year while I was still in New Jersey.

(Silly boy) Told my girl we had to break up
(Silly boy) Thought that she would call my bluff
(Silly boy) But she said to my surprise
Big girls don’t cry

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Crying—emotional tearing—is uniquely human.5 Investigators from the Weizman Institute in Rehovot, Israel, carried out an imaginative, intricate, and compelling series of experiments to show that human tears contain a chemosignal with profound effects. Men who sniffed odorless tears, obtained from women in circumstances with no emotional content, experienced reduced sexual appeal for the women, less sexual arousal, reduced physiologic measures of arousal, lowered testosterone, and concomitant changes in brain magnetic resonance images. Powerful stuff, these tears. “Not tonight, dear” would seem to be the simple message—an evolutionary signal. What else might be in tears? Where else might these or similar chemosignals be found? What are the active compound(s)? What are their mechanism of action? What else might they do? How might tears be involved in the changes we see in our patients with eye disease? Maybe there’s more to the eye than PERRLA. the rheumatologist

Dr. Panush is professor of medicine, Division of Rheumatology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles.

References

  1. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for choloroquine and hydroxychooroquine retinopathy. Ophthalmology. 2011;118:415-422.
  2. Falk RL, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener’s): An alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63:863-864.
  3. Matteson E, Panush RS. Eponyms should be abandoned. Rheumatology News. December 2007;6:12.
  4. Panush RS, Wallace DJ, Dorff EN, Engleman EP. Retraction of the suggestion to use the term “Reiter’s syndrome” 64 years later: The legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum. 2007;56: 693-694.
  5. Gelstein S, Yeshurun Y, Rosenkrantz L, et al. Human tears contain a chemosignal. Science. 2011;331:226-230.

Page: 1 2 3 | Single Page
Share: 

Filed under:Practice SupportProfiles Tagged with:HYDROXYCHLOROQUINEpatient carePractice ManagementretinarheumatologistTreatment

Related Articles

    Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

    November 16, 2016

    Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    Watch Those Eyes

    December 1, 2007

    What you need to know about Uveitis in Rheumatic Diseases

    An Overview of Pediatric, Noninfectious Uveitis

    October 18, 2018

    Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences